Research

Researcher setting up genetic samples and primers for polymerase chain reaction

Parkinson's Disease and other movement disorders

Hope through research

The USF Health Byrd Parkinson's Disease & Movement Disorders Center evaluates and develops new medications and surgical procedures for Parkinson's Disease. Under Dr. Hauser's leadership, we conduct multiple independent and sponsored studies, pioneering advancements in treatment through research and innovation.

PPMI

 

Brief summary: Take the Smell Test Challenge Today!   Smell loss can be linked to brain disease.  Researchers are studying this link to learn more about the connection. Not everyone with smell loss will develop a brain disease.  Request a scratch-and-sniff test to help scientists learn more about this risk factor.

Status: Recruiting (by cohort - contact our Center for details ) - To request a free smell test, visit:

https://mysmelltest.org/sf01

 

Illustration of images of genes (red, green and blue spots) are superimposed on images of multi-well plates

Catalpa

NCT06937931

Brief summary: The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults.

Status: Enrolling

https://clinicaltrials.gov/study/NCT06937931

 

 

 

 

 

microscope

Padova

ID: NCT04777331

Brief summary: A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

Status: Active, not recruiting

https://clinicaltrials.gov/study/NCT04777331?tab=results

 

P22-487

ID: NCT06107426

Brief summary: Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease (ROSSINI)

Status: Maintaining

https://www.clinicaltrials.gov/study/NCT06107426

 

 

Human breast cancer cells

Neulark

Brief summary: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)

Status: Enrolling

https://clinicaltrials.gov/study/NCT06680830

 

Pasadena

ID: NCT03100149

Brief summary: This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. 

Status: Maintaining

https://clinicaltrials.gov/study/NCT03100149

Cerevance

CVN424-301

Brief summary: A study to assess the efficacy of CVN424 dosed once daily, compared to placebo, for change in OFF time in Parkinson’s Disease.

Status: Enrolling

https://clinicaltrials.gov/study/NCT06553027

Truebinding

NCT06773962

Brief summary: The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).

Status: Enrolling

https://clinicaltrials.gov/study/NCT06773962

 

TEVA

NCT06568237

Brief summary: A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study (TOPAS-MSA)

Status: Enrolling

https://clinicaltrials.gov/study/NCT06568237

 

LUMA

NCT05348785

Brief summary: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 (LUMA)

Status: Maintaining

https://clinicaltrials.gov/study/NCT05348785

Support

Our clinical trials enable us to innovate and discover new, effective treatments for Parkinson's disease and other movement disorders. The importance of our work cannot be overstated, as it brings us closer to a cure and improves the quality of life for countless patients. Donations are crucial to sustaining this vital research and ensuring ongoing progress.

 

To support our mission, click here or reach out to Katie Dorsey at kbdorsey@usf.edu or (813) 974-1608.